Quadrise (LSE:QED)'s exclusive emulsifier agreement with Nouryon has expired without renewal, ending a long-standing exclusive arrangement while the company runs a strategic review and progresses key customer projects.
What's happening
The lapse means Quadrise no longer has an exclusive Supply and collaboration framework with the chemicals group that provides the emulsifiers used in its fuel technologies. In an announcement titled "Nouryon update" on 11 November 2026, the company said its Exclusive Global Collaboration and Emulsifiers Sales Agreement with Nouryon expired on 31 October 2026. It will not be extended or replaced until Quadrise's project and Volume requirements are confirmed. In practical terms, supply continues on a looser basis: Nouryon remains interested in a future agreement and will keep supporting trials through individual orders, while Quadrise develops alternative additive supplies.
The shares moved lower on the news. Quadrise (LSE:QED) shares moved 34% lower in the week to 13 November 2026. The company confirmed that its exclusive supply agreement with Nouryon had expired and that the agreement will not be renewed until the company has secured sufficiently firm commercial arrangements.
The latest announcement
The key points were:
- The Exclusive Global Collaboration and Emulsifiers Sales Agreement with Nouryon expired on 31 October 2026.
- It will not be extended or replaced until Quadrise's project and volume requirements are confirmed.
- Nouryon remains interested in a future agreement and will support trials through individual orders.
- Quadrise has done significant development work on alternative additive supplies, including emulsifiers.
- Bespoke formulation testing is under way at its laboratory facility, aimed at broadening its global additive supply base and strengthening its MSAR® and bioMSAR™ products.
The news marks a change from earlier in the year. On 12 January 2026, Quadrise announced an "Extension of Exclusive Agreement with Nouryon". Ten months later, that exclusive arrangement has ended, with any replacement tied to the company firming up its commercial pipeline.
The Business at a glance
Quadrise (LSE:QED) develops fuel technologies marketed as MSAR® and bioMSAR™, which rely on emulsifiers and other additives. That is why the supplier relationship with Nouryon matters: emulsifiers are a core input. The company's commercial progress depends on converting trials and partnerships into paying, volume-based business.
Several strands of that pipeline were set out in the "Final Results, Notice of AGM, Strategic Review" announcement on 26 October 2026, covering the financial year to 30 June 2026:
- Marine trials progressing with MSC and Cargill.
- Refinery engagement indicating potential Margin improvements of US$15–25 million for a mid-sized refinery.
- OEM approval granted for a commercial trial at OCP in Morocco.
- A strategic review launched to accelerate commercialisation, with Options including master licensing, joint ventures or strategic investment.
In the US, Valkor is preparing to deploy its 600 barrels per day Multifuel Manufacturing Unit (MMU) and associated equipment in Utah. A "Valkor update" on 2 November 2026 said Valkor expects to pay US$300,000 of the outstanding US$950,000 site licence fee, which was due on 31 October 2026, in early November 2026. The remaining US$650,000 is to be paid on completion of Valkor's fundraising, expected in Q4 2026. Shipment and mobilisation are planned after Valkor pays the outstanding balance.
Financial position
The final results showed a loss after tax of £4.2 million for the year to 30 June 2026, compared with £3.1 million in the prior year. Cash fell to £2.1 million from £5.9 million. The company said its funding runway is expected to extend to September 2027.
That runway gives Quadrise some time, but the cash balance is modest relative to its annual loss. The strategic review, the Valkor licence payments and any progress on marine, refinery and Moroccan trials are therefore central to the outlook. The Nouryon announcement adds to the sense that commercial volumes have yet to be confirmed, since the company itself linked any new agreement to confirmation of its project and volume requirements.
Factors to watch
Investors following Quadrise may want to weigh the following:
- Supply and partner risk: without an exclusive agreement, Quadrise relies on individual orders from Nouryon for trials and on developing alternative additive supplies. Any problems qualifying new emulsifiers could affect product performance or timing.
- Commercialisation risk: the company says new terms with Nouryon depend on confirming project and volume requirements, which signals that firm commercial volumes are not yet in place.
- Customer and counterparty risk: the Valkor project in Utah depends on Valkor paying its outstanding licence fee and completing a fundraising, expected in Q4 2026. A delay would push back shipment and mobilisation.
- Funding and dilution risk: with cash of £2.1 million and a loss after tax of £4.2 million in the last financial year, the company could need further funding beyond its stated runway to September 2027. Any share issue would dilute existing shareholders.
- Strategic review uncertainty: options such as master licensing, joint ventures or strategic Investment could reshape the business, but there is no guarantee of a deal or of its terms.
- Share price movement: a 34% weekly move shows how sensitive the shares are to news about partners and timelines.
What to watch next
Key items to monitor include:
- Confirmation of Valkor's US$300,000 payment and the timing of the remaining US$650,000 balance.
- Any update from the strategic review, including whether a licensing, joint venture or investment route emerges.
- Progress on the marine trials with MSC and Cargill and the commercial trial at OCP in Morocco.
- Results from bespoke formulation testing of alternative emulsifiers at the laboratory facility.
- Whether a new agreement with Nouryon is reached once project and volume requirements are confirmed.
The bottom line
The expiry of the Nouryon exclusive agreement does not cut Quadrise off from its emulsifier supplier, since Nouryon will continue to support trials through individual orders and remains interested in a future deal. But it removes a formal framework at a time when the company is running a strategic review, managing a modest cash balance and waiting for customers such as Valkor to move forward. The share price move reflects the market weighing how quickly firm commercial volumes can follow.




_11_17_2026_11_34_21_713195.jpg)

Please wait processing your request...